Product defect alert: Emerade ® all strengths

An alert was issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for Emerade ® on Thursday 11 July 2019.

The manufacturers for Emerade®, Bausch & Lomb UK limited, have informed us that there is a risk of Emerade® failing to deliver a dose of adrenaline from the syringe due to a blockage of the needle. Bausch & Lomb UK Limited are not recalling Emerade.

All Emerade® pens currently on the market have a low risk (2 in every 1000) of being defective however it is not possible to notice a faulty device by looking at it. This alert applies to all three strengths of Emerade® (150 micrograms, 300 micrograms and 500 micrograms). The manufacturers of Emerade® advised that this issue should be resolved for the newly manufactured auto-injectors by mid-July 2019.

Please note that your GP or other prescribers will not issue a third adrenaline auto-injector as a result of this defect.

If this alert affects you or a family member, please remember to:

  1. Carry two pens with you at all times
  2. Check the expiry date and replace the pen before it expires
  3. If you need to use your Emerade® and still feel unwell after your first injection you should administer your second pen without delay.
  4. Please click here for the MHRA “Adrenaline auto-injectors: advice on use” information.